We are live on ! Find out more
MC

Muhlenkamp & Co Portfolio holdings

AUM $380M
1-Year Est. Return 43.74%
This Fund
S&P 500
This Quarter Est. Return
+2.55%
1 Year Est. Return
+43.74%
3 Year Est. Return
+121.38%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$262M
AUM Growth
-$13.6M
Cap. Flow
-$15.5M
Cap. Flow %
-5.91%
Top 10 Hldgs %
49.65%
Holding
38
New
1
Increased
1
Reduced
8
Closed
1

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$6.07M
2
PFE icon
Pfizer
PFE
+$8.85K

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$11.3M
2
GILD icon
Gilead Sciences
GILD
+$6.08M
3
ON icon
ON Semiconductor
ON
+$4.18M
4
DD icon
DuPont de Nemours
DD
+$4.35K
5
ESRX
Express Scripts Holding Company
ESRX
+$3.6K

Sector Composition

Rank Sector Weight
1 Healthcare 25.81%
2 Technology 23.38%
3 Consumer Discretionary 12.41%
4 Financials 8.53%
5 Materials 7.23%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LCI
26
DELISTED
Lannett Company, Inc.
LCI
$3.71M 1.41%
68,111
-45
-0.1% -$2.83K
GLOP
27
DELISTED
GASLOG PARTNERS LP
GLOP
$2.85M 1.09%
119,505
– –
NLY icon
28
Annaly Capital Management
NLY
$16.9B
$2.4M 0.91%
58,262
– –
PKW icon
29
Invesco BuyBack Achievers ETF
PKW
$1.69B
$2.06M 0.79%
36,381
– –
AMLP icon
30
Alerian MLP ETF
AMLP
$12.7B
$1.9M 0.72%
37,548
– –
ALLY icon
31
PUT
Ally Financial
ALLY
$14B
$1.23M 0.47%
46,800
– –
PFE icon
32
Pfizer
PFE
$143B
$997K 0.38%
28,969
+259
+0.9% +$8.85K
RUSHB icon
33
Rush Enterprises Class B
RUSHB
$5.89B
$249K 0.1%
12,749
– –
GILD icon
34
CALL
Gilead Sciences
GILD
$167B
$156K 0.06%
2,200
– –
EGO icon
35
Eldorado Gold
EGO
$7.28B
$10K ﹤0.01%
2,000
– –
BMY icon
36
Bristol-Myers Squibb
BMY
$124B
– –
-178,436
Closed -$11.3M
1
2

Similar funds

AC
Attestor Capital Grand Cayman, Cayman Islands $380M AUM
MW
Marks Wealth Annapolis, Maryland $380M AUM 40.02% 1-Year Est. Return
EAM
Empirical Asset Management Wellesley, Massachusetts $379M AUM 24.52% 1-Year Est. Return
RWA
Rooted Wealth Advisors Bourbonnais, Illinois $379M AUM 13.75% 1-Year Est. Return
CSWG
Cardinal Strategic Wealth Guidance Louisville, Kentucky $379M AUM 19.59% 1-Year Est. Return
BP
BWM Planning The Woodlands, Texas $379M AUM 21.72% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
KFS
Kurt F. Somerville $379M AUM 19.42% 1-Year Est. Return

Muhlenkamp & Co's Q2 2018 Portfolio in Review

As of Q2 2018, Muhlenkamp & Co held 38 positions worth $262M, down 4.9% from $276M the previous quarter. Its ten largest holdings account for 50% of the portfolio.

Muhlenkamp & Co withdrew a net $15.5M in Q2 2018, closing 1 position and reducing 8 holdings. Its most notable exit was Bristol-Myers Squibb, an estimated $11.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 26% of assets, down from 28% a quarter earlier, followed by Technology and Consumer Discretionary.

Against the trend, Muhlenkamp & Co opened a new position in Jazz Pharmaceuticals worth $6.4M.

  • Muhlenkamp & Co's largest Q2 2018 buy was Jazz Pharmaceuticals: 37,155 shares worth $6.4M.
  • Muhlenkamp & Co added most to Pfizer in Q2 2018, an estimated $8.85K increase.
  • Muhlenkamp & Co's biggest Q2 2018 reduction was Gilead Sciences, cutting an estimated $6.08M.
  • Muhlenkamp & Co fully exited Bristol-Myers Squibb in Q2 2018, selling an estimated $11.3M.
  • Muhlenkamp & Co's ten largest holdings make up 50% of its $262M portfolio in Q2 2018.
  • Muhlenkamp & Co opened 1 new position and closed 1 in Q2 2018.
  • Muhlenkamp & Co's portfolio value fell 4.9% quarter-over-quarter to $262M.

Based on Muhlenkamp & Co's 13F filing for Q2 2018, filed 13 Aug 2018.